Moderna exceeds revenue expectations by over USD 700m
The US-based vaccine maker only has a single approved product on the market, which has just booked a USD 4.5bn revenue in the second quarter.
by marketwire, translated by daniel pedersen
US-based vaccine maker Moderna generated USD 4.75bn in revenues during the second quarter of 2022, of which USD 4.5bn came from a single product: its Covid-19 vaccine.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Valneva plunges after Europe slashes Covid-19 vaccine order
For subscribers
Novavax's Covid-19 vaccine backed by CDC experts
For subscribers
